CN114786776B - 针对ceacam5和cd3的双特异性抗体 - Google Patents

针对ceacam5和cd3的双特异性抗体

Info

Publication number
CN114786776B
CN114786776B CN202080073507.3A CN202080073507A CN114786776B CN 114786776 B CN114786776 B CN 114786776B CN 202080073507 A CN202080073507 A CN 202080073507A CN 114786776 B CN114786776 B CN 114786776B
Authority
CN
China
Prior art keywords
seq
ser
thr
gly
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080073507.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN114786776A (zh
Inventor
K·斯特林
S·马约基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramkap Biological Alpha Co ltd
Original Assignee
Ramkap Biological Alpha Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramkap Biological Alpha Co ltd filed Critical Ramkap Biological Alpha Co ltd
Publication of CN114786776A publication Critical patent/CN114786776A/zh
Application granted granted Critical
Publication of CN114786776B publication Critical patent/CN114786776B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202080073507.3A 2019-09-18 2020-09-17 针对ceacam5和cd3的双特异性抗体 Active CN114786776B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962902150P 2019-09-18 2019-09-18
US62/902,150 2019-09-18
EP19198124.0 2019-09-18
EP19198124 2019-09-18
PCT/IB2020/058690 WO2021053587A1 (en) 2019-09-18 2020-09-17 Bispecific antibodies against ceacam5 and cd3

Publications (2)

Publication Number Publication Date
CN114786776A CN114786776A (zh) 2022-07-22
CN114786776B true CN114786776B (zh) 2026-03-24

Family

ID=72615918

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080073507.3A Active CN114786776B (zh) 2019-09-18 2020-09-17 针对ceacam5和cd3的双特异性抗体

Country Status (18)

Country Link
US (2) US12441807B2 (enExample)
EP (1) EP4013512B1 (enExample)
JP (1) JP7701911B2 (enExample)
KR (1) KR20220113353A (enExample)
CN (1) CN114786776B (enExample)
AU (1) AU2020350205A1 (enExample)
BR (1) BR112022004995A2 (enExample)
CL (1) CL2022000663A1 (enExample)
CO (1) CO2022004685A2 (enExample)
ES (1) ES2975528T3 (enExample)
HR (1) HRP20240626T1 (enExample)
HU (1) HUE067160T2 (enExample)
IL (1) IL291482A (enExample)
MX (1) MX2022003110A (enExample)
PE (1) PE20221045A1 (enExample)
PL (1) PL4013512T3 (enExample)
RS (1) RS65480B1 (enExample)
WO (1) WO2021053587A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020350205A1 (en) 2019-09-18 2022-05-12 Lamkap Bio Alpha AG Bispecific antibodies against CEACAM5 and CD3
US11433100B2 (en) 2020-08-20 2022-09-06 A2 Biotherapeutics, Inc. Compositions and methods for treating ceacam positive cancers
WO2022040454A1 (en) 2020-08-20 2022-02-24 A2 Biotherapeutics, Inc. Compositions and methods for treating mesothelin positive cancers
EP4097486A4 (en) 2020-08-20 2023-09-06 A2 Biotherapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING CEACAM POSITIVE CANCER
EP4490192A1 (en) 2022-03-07 2025-01-15 Novimmune S.A. Cd28 bispecific antibodies for targeted t cell activation
WO2023174925A1 (en) 2022-03-14 2023-09-21 Novimmune Sa Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
MX2024011519A (es) 2022-03-23 2024-09-24 Synaffix Bv Conjugados de anticuerpos para el direccionamiento contra tumores que expresan el antigeno carcinoembrionario.
CN116925232A (zh) * 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 靶向ceacam和cd3的多特异性抗体及其用途
CN119998319A (zh) 2022-06-16 2025-05-13 拉姆卡普生物测试有限公司 针对ceacam5和cd47的双特异性抗体与针对ceacam5和cd3的双特异性抗体的组合治疗
AU2023362569A1 (en) 2022-10-21 2025-04-24 Novimmune Sa Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation
AU2023415595A1 (en) * 2022-12-30 2025-07-17 Merus B.V. Promiscuous cd3 binding molecules
US20250043001A1 (en) 2023-03-14 2025-02-06 Xencor, Inc. Anti-cd28 compositions
CN122206704A (zh) * 2023-11-09 2026-06-12 多安生物治疗有限公司 抗ceacam5抗体及其用途
CN121248779A (zh) * 2024-06-25 2026-01-02 冕屹立生物技术(上海)有限公司 靶向人cd3分子的抗体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107849137A (zh) * 2015-10-02 2018-03-27 豪夫迈·罗氏有限公司 双特异性抗ceaxcd3 t细胞活化性抗原结合分子

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
US20020165360A1 (en) 2000-11-30 2002-11-07 Junghans Richard P. Chimeric effector cell receptors against carcinoembryonic antigen
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US8613922B2 (en) 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US8236308B2 (en) 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
NZ569204A (en) 2005-12-21 2012-03-30 Micromet Ag Pharmaceutical compositions with resistance to soluble CEA - comprising antibodies that bind to CD3 and CEA
IL177158A0 (en) 2006-07-30 2008-01-20 Assaf Klar Method for designing and implementing improved longitudinal flexibility multilayered pipeline
WO2008119565A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific binding domain
PL2155788T3 (pl) 2007-04-03 2013-02-28 Amgen Res Munich Gmbh Swoiste międzygatunkowe bispecyficzne czynniki wiążące
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
KR20090010580A (ko) 2007-07-24 2009-01-30 조용식 페트용 토이렛
CA2711370C (en) 2008-01-15 2017-06-13 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
PT3056515T (pt) 2008-01-15 2019-07-19 Univ Leland Stanford Junior Métodos para manipulação da fagocitose mediada por cd47
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
MX2011003502A (es) 2008-10-01 2011-09-01 Micromet Ag Anticuerpo de cadena sencilla biespecifica de psmaxcd3 especifico a traves de especies.
EP2352763B2 (en) 2008-10-01 2022-09-21 Amgen Research (Munich) GmbH Bispecific single chain antibodies with specificity for high molecular weight target antigens
AU2009299794B2 (en) 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
WO2011034660A1 (en) 2009-09-16 2011-03-24 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
AU2011252851B2 (en) 2010-05-14 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to CD47
WO2012023053A2 (en) 2010-08-16 2012-02-23 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
KR101981342B1 (ko) 2011-03-02 2019-05-22 로슈 글리카트 아게 Cea 항체
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
US20140242081A1 (en) 2011-07-18 2014-08-28 Micromet Ag Dosing regimens for treatment of cea-expressing cancers
BR112014002353B1 (pt) 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
KR101870555B1 (ko) 2011-08-23 2018-06-22 로슈 글리카트 아게 T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
SI2766397T1 (sl) 2011-10-11 2018-09-28 F. Hoffmann-La Roche Ag Izboljšano sestavljanje bispecifičnih protiteles
ES2767135T3 (es) 2011-10-19 2020-06-16 Novimmune Sa Métodos para purificar anticuerpos
ME03512B (me) 2012-02-06 2020-04-20 Inhibrx Inc Cd47 antitijela i postupci za njihovu upotrebu
US20140140989A1 (en) 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
PT3199552T (pt) 2012-11-20 2020-03-25 Sanofi Sa Anticorpos anti-ceacam5 e suas utilizações
RU2693078C2 (ru) 2012-12-03 2019-07-01 Новиммун С.А. Анти-cd47 антитела и способы их применения
CN104936985A (zh) 2013-02-26 2015-09-23 罗切格利卡特公司 双特异性t细胞活化性抗原结合分子
CN110437337B (zh) 2013-02-26 2024-07-30 罗切格利卡特公司 双特异性t细胞活化性抗原结合分子
AU2014309199B2 (en) 2013-08-20 2018-04-19 Merck Sharp & Dohme Llc Treating cancer with a combination of a PD-1 antagonist and dinaciclib
US11046763B2 (en) 2014-01-08 2021-06-29 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
WO2015112534A2 (en) 2014-01-21 2015-07-30 Medimmune, Llc Compositions and methods for modulating and redirecting immune responses
CN106604933B (zh) 2014-07-11 2021-08-10 文塔纳医疗系统公司 抗pd-l1抗体及其诊断用途
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
WO2016036678A1 (en) 2014-09-02 2016-03-10 Medimmune, Llc Formulations of bispecific antibodies
EP3261678B8 (en) 2015-01-23 2021-03-17 Helix Biopharma Corp. Antibody-urease conjugates for therapeutic purposes
ES2752054T3 (es) 2015-03-31 2020-04-02 Novimmune Sa Método para optimizar el ensamble y producción de complejos de proteínas heteromultiméricas
GB2546072B (en) 2016-01-05 2019-07-10 Bja Trading Ltd Attachment assembly and method of using same
BR112018011029A2 (pt) 2016-01-08 2018-11-21 Hoffmann La Roche métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits
KR20240016445A (ko) 2016-04-15 2024-02-06 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법
WO2017196793A1 (en) 2016-05-09 2017-11-16 Celgene Corporation Cd47 antibodies and methods of use thereof
EP3493845A4 (en) 2016-08-03 2020-04-15 The Board of Trustees of the Leland Stanford Junior University INTERRUPTION OF FC RECEPTOR USE ON MACROPHAGES TO IMPROVE THE EFFECTIVENESS OF ANTI-SIRPALPHA ANTIBODY THERAPY
WO2018053328A1 (en) 2016-09-16 2018-03-22 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
KR102329635B1 (ko) 2017-04-24 2021-11-22 재단법인 목암생명과학연구소 Her3 및 cd3에 결합하는 이중특이적 항체
US11200906B2 (en) 2017-09-15 2021-12-14 Lg Electronics, Inc. Audio encoding method, to which BRIR/RIR parameterization is applied, and method and device for reproducing audio by using parameterized BRIR/RIR information
CN111212660A (zh) 2017-12-14 2020-05-29 豪夫迈·罗氏有限公司 Cea cd3双特异性抗体和pd-1轴结合拮抗剂在治疗癌症的剂量方案中的用途
EP3752190B1 (en) 2018-02-12 2022-07-06 Forty Seven, Inc. Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies
CN120399075A (zh) 2018-03-14 2025-08-01 诺维莫尼公司 抗-CD3ε抗体及其应用方法
CN112566938B (zh) 2018-06-03 2025-04-01 拉姆卡普生物测试有限公司 针对ceacam5和cd47的双特异性抗体
AU2020350205A1 (en) 2019-09-18 2022-05-12 Lamkap Bio Alpha AG Bispecific antibodies against CEACAM5 and CD3

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107849137A (zh) * 2015-10-02 2018-03-27 豪夫迈·罗氏有限公司 双特异性抗ceaxcd3 t细胞活化性抗原结合分子

Also Published As

Publication number Publication date
JP2022548947A (ja) 2022-11-22
MX2022003110A (es) 2022-06-27
EP4013512B1 (en) 2024-02-14
US20230136228A1 (en) 2023-05-04
ES2975528T3 (es) 2024-07-08
CL2022000663A1 (es) 2023-01-06
RS65480B1 (sr) 2024-05-31
WO2021053587A1 (en) 2021-03-25
CN114786776A (zh) 2022-07-22
HUE067160T2 (hu) 2024-10-28
IL291482A (en) 2022-05-01
EP4013512C0 (en) 2024-02-14
HRP20240626T1 (hr) 2024-08-02
US20260109779A1 (en) 2026-04-23
AU2020350205A1 (en) 2022-05-12
BR112022004995A2 (pt) 2022-06-21
PL4013512T3 (pl) 2024-06-10
EP4013512A1 (en) 2022-06-22
US12441807B2 (en) 2025-10-14
CA3150265A1 (en) 2021-03-25
PE20221045A1 (es) 2022-06-22
JP7701911B2 (ja) 2025-07-02
CO2022004685A2 (es) 2022-07-08
KR20220113353A (ko) 2022-08-12

Similar Documents

Publication Publication Date Title
CN114786776A (zh) 针对ceacam5和cd3的双特异性抗体
JP7755634B2 (ja) アクチビン２型受容体結合タンパク質及びその使用
CN108779180B (zh) 新型抗-pd-l1抗体
CN107922503B (zh) 一种pdl-1抗体、其药物组合物及其用途
AU2019201141B2 (en) Novel antibody binding to TFPI and composition comprising the same
KR20220147642A (ko) Il4r에 결합하는 항체 및 이의 용도
CN111196854A (zh) Ox40抗体及其制备方法和应用
CN115785268B (zh) 抗cd47抗体及其用途
CN119095873A (zh) 用于靶向杀伤GPC3阳性恶性细胞的双特异性GPC3xCD28和GPC3xCD3抗体及其组合
RU2827106C1 (ru) Биспецифические антитела против ceacam5 и cd3
CN111303288B (zh) 一种分离的结合抗原psma的蛋白及其用途
HK40075893A (en) Bispecific antibodies against ceacam5 and cd3
CA3150265C (en) Bispecific antibodies against ceacam5 and cd3
HK40089230A (en) Pharmaceutical composition and use
CN118159559A (zh) 一种抗b7-h4抗体及其制备方法和应用
HK40032298A (en) Novel anti-pd-l1 antibodies
HK40032298B (en) Novel anti-pd-l1 antibodies
HK1260737B (en) Novel anti-pd-l1 antibodies
HK1260737A1 (en) Novel anti-pd-l1 antibodies
HK40002449B (en) Activin type 2 receptor binding proteins and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40075893

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant